GSK Expands Shingrix Collaboration in China #

GSK has extended its partnership to commercialize the shingles vaccine, Shingrix, in China until 2034. This agreement sets expectations for significant sales, estimating purchases of up to 2.3 billion British pounds ($2.92 billion) from 2024 to 2029 based on current exchange rates. The previous minimum purchase requirements for Shingrix by China’s leading vaccine maker are no longer applicable, potentially allowing for more flexible procurement aligned with market demands. This collaboration reflects GSK’s ongoing commitment to increase access to its vaccines in the Chinese market.